Chinese
drug approval boosts AstraZeneca's lung cancer hopes
Send a link to a friend
[March 27, 2017] By
Ben Hirschler
LONDON (Reuters) - AstraZeneca has won
approval for its lung cancer pill Tagrisso in China, a key market for
the potential blockbuster medicine.
|
Tagrisso is designed to help cancer patients with certain genetic
mutations that are very common in China and the regulatory green
light boosts the British drugmaker's prospects in a key therapy
area.
Lung cancer is a vital component of AstraZeneca's ambitious sales
targets, set in 2014 in response to a takeover attempt by Pfizer,
with Tagrisso forecast to contribute $3 billion.
At the time, many analysts viewed the Tagrisso goal as unrealistic.
Yet consensus forecasts have now risen to $2.8 billion for 2022,
according to Thomson Reuters data, helped by its strong launch and
the failure of some rival products.
Tagrisso sales last year totaled $423 million.
China is potentially the biggest market for the drug because 30 to
40 percent of Asian patients with non-small cell lung cancer have
epidermal growth factor receptor mutated tumors that are receptive
to Tagrisso, a far higher rate than in the West.
AstraZeneca's head of drug development, Sean Bohen, said in a
statement on Monday announcing the drug's approval that China
represented a "significant opportunity".
Tagrisso is the first drug approved under the China Food and Drug
Administration’s priority review pathway, which offers a fast track
to market for an innovative medicines.

[to top of second column] |

The once-daily pill is currently used as a second-line therapy,
after patients have tried older drugs like Roche's Tarceva and
AstraZeneca's own Iressa, although a clinical trial this year could
prove its benefit in first-line use.

Beyond Tagrisso, investors are heavily focused on prospects for
another clinical study testing a combination of two drugs in the hot
area of immunotherapy, where AstraZeneca is chasing rivals such as
Merck , Bristol-Myers Squibb and Roche.
(Reporting by Ben Hirschler; editing by Susan Thomas)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|